NCT07623473 Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation
| NCT ID | NCT07623473 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Herlev and Gentofte Hospital |
| Condition | Lung Cancer (Diagnosis) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,800 participants |
| Start Date | 2024-05-22 |
| Primary Completion | 2028-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,800 participants in total. It began in 2024-05-22 with a primary completion date of 2028-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule. Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.
Eligibility Criteria
Inclusion Criteria: * Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit * Having signed informed consent Exclusion Criteria: * Active cancer, excluding non-melanoma skin cancer * Comorbidities that exclude the patient from clinical follow-up and final diagnosis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07623473 clinical trial?
This trial is open to participants of all sexes, studying Lung Cancer (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07623473 currently recruiting?
Yes, NCT07623473 is actively recruiting participants. Contact the research team at soeren.egstrand@regionh.dk for enrollment information.
Where is the NCT07623473 trial being conducted?
This trial is being conducted at Gentofte Municipality, Denmark.
Who is sponsoring the NCT07623473 clinical trial?
NCT07623473 is sponsored by Herlev and Gentofte Hospital. The trial plans to enroll 1,800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.